After an earlier rejection that drew criticism from some observers, the FDA quickly accepted Stealth BioTherapeutics’ new ...

The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures ...

Susan Monarez told Senators at a hearing Wednesday that Robert F. Kennedy Jr. pushed her out for refusing to rubber-stamp ...

A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

After a tumultuous two-day meeting marked by confusion and missteps, an advisory committee endorsed guidelines that would ...

T.Rx Capital was co-founded by Michael Langer, former Pear Therapeutics CEO Corey McCann and Eli Lilly veteran Kwesi Frimpong ...

Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for ...

Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and ...

Pfizer and Arvinas plan to out-license their partnered drug vepdegestrant. Elsewhere, Novo shared more data for oral Wegovy ...

The committee reconvened Friday to re-do a vote on coverage of the combined MMRV shot through the Vaccines for Children ...

A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis ...